Avertix Medical, Heart & Rhythm Institute announce partnership

Avertix Medical (AVRT) announced they have entered into an agreement to make the Guardian System, the first and only FDA-approved implantable heart attack detection and warning system, available to the Heart & Rhythm Institute of Trinity and its collaborative group of cardiologists who work across seven cardiology practices and serve seven hospitals in the area. This partnership seeks to enhance the Heart & Rhythm Institute’s commitment to redefining the future of cardiac care with cutting-edge technology. Avertix’s Guardian System is designed to detect acute coronary syndrome events, such as heart attacks-even silent and atypical symptomatic heart attacks-in real time. “We are pleased to announce the offering of our Guardian System at a leading cardiology ambulatory surgery center in the Tampa Bay area which is served by truly innovative physicians dedicated to providing the highest-quality care for their patients,” said Tim Moran, President and Chief Executive Officer of Avertix. On May 3, 2023, Avertix Medical, Inc. and BIOS Acquisition Corporation (BIOS) announced that they entered into a definitive agreement for a business combination. Upon completion of the Transaction, the combined company’s common stock is expected to be listed on Nasdaq under the ticker symbol “AVRT.”